Literature DB >> 20376084

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.

O Kosmider, V Gelsi-Boyer, L Slama, F Dreyfus, O Beyne-Rauzy, B Quesnel, M Hunault-Berger, B Slama, N Vey, C Lacombe, E Solary, D Birnbaum, O A Bernard, M Fontenay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20376084     DOI： 10.1038/leu.2010.52

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  79 in total

1.  An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity.

Authors:  Lucas A Luna; Zachary Lesecq; Katharine A White; An Hoang; David A Scott; Olga Zagnitko; Andrey A Bobkov; Diane L Barber; Jamie M Schiffer; Daniel G Isom; Christal D Sohl
Journal:  Biochem J       Date:  2020-08-28       Impact factor: 3.857

2.  TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.

Authors:  Jumpei Yamazaki; Jaroslav Jelinek; Yue Lu; Matteo Cesaroni; Jozef Madzo; Frank Neumann; Rong He; Rodolphe Taby; Aparna Vasanthakumar; Trisha Macrae; Kelly R Ostler; Hagop M Kantarjian; Shoudan Liang; Marcos R Estecio; Lucy A Godley; Jean-Pierre J Issa
Journal:  Cancer Res       Date:  2015-05-13       Impact factor: 12.701

Review 3.  Epigenetic aspects of MDS and its molecular targeted therapy.

Authors:  Jumpei Yamazaki; Jean-Pierre J Issa
Journal:  Int J Hematol       Date:  2012-10-10       Impact factor: 2.490

4.  Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.

Authors:  Yiqun Zhang; Hui Wei; Kejing Tang; Dong Lin; Cuiping Zhang; Yingchang Mi; Lin Wang; Cuicui Wang; Min Wang; Jianxiang Wang
Journal:  Genet Test Mol Biomarkers       Date:  2012-07-18

5.  I walk the line: how to tell MDS from other bone marrow failure conditions.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 6.  Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.

Authors:  Guillermo Montalbán Bravo; Elinor Lee; Bryan Merchan; Hagop M Kantarjian; Guillermo García-Manero
Journal:  Br J Haematol       Date:  2014-06-05       Impact factor: 6.998

Review 7.  Updates in cytogenetics and molecular markers in MDS.

Authors:  Ramon V Tiu; Valeria Visconte; Fabiola Traina; Anita Schwandt; Jaroslaw P Maciejewski
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

8.  Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Authors:  F Traina; V Visconte; P Elson; A Tabarroki; A M Jankowska; E Hasrouni; Y Sugimoto; H Szpurka; H Makishima; C L O'Keefe; M A Sekeres; A S Advani; M Kalaycio; E A Copelan; Y Saunthararajah; S T Olalla Saad; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

9.  IDH1 Associated with Neuronal Apoptosis in Adult Rats Brain Following Intracerebral Hemorrhage.

Authors:  Xing Chen; Hongmei Wang; Weibing Yu; Fen Chen; Guiyun Wang; Jiajia Shi; Chunying Zhou
Journal:  Cell Mol Neurobiol       Date:  2016-08-27       Impact factor: 5.046

Review 10.  The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?

Authors:  Zaher K Otrock; Ramon V Tiu; Jaroslaw P Maciejewski; Mikkael A Sekeres
Journal:  Expert Rev Hematol       Date:  2013-02       Impact factor: 2.929
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.